Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Q: Context: The week 3 matchup vs. the Texans proved to be a greater challenge for the Patriots than the Saints had been in week 2. The Patriots scored first on a 7-play drive ending with a Tom Brady 5-yard throw to Rob Gronkowski, who was playing with a groin injury that took him out of the previous week's game. The game would progress through seven lead changes, as Texans rookie quarterback DeShaun Watson would go drive-for-drive against Brady. Watson threw two touchdowns, one of which to his tight end Ryan Griffin, who attended college in New England at Connecticut. Two field goals late in the game would give the Texans their final lead at 33-28. With less than 2:25 remaining in the game, Brady led the Patriots on a frantic 8-play 71-yard drive that culminated in a 25-yard reception by Brandin Cooks to give the Patriots the 36-33 win. 
 Question: Who did the Patriots beat before beating the Texans?

A: saints
****
Q: Context: Our previous work has shown that gene knockout of the sodium-glucose cotransporter SGLT2 modestly lowered blood glucose in streptozotocin-diabetic mice (BG; from 470 to 300 mg/dl) and prevented glomerular hyperfiltration but did not attenuate albuminuria or renal growth and inflammation. Here we determined effects of the SGLT2 inhibitor empagliflozin (300 mg/kg of diet for 15 wk; corresponding to 60-80 mgkg(-1)day(-1)) in type 1 diabetic Akita mice that, opposite to streptozotocin-diabetes, upregulate renal SGLT2 expression. Akita diabetes, empagliflozin, and Akita + empagliflozin similarly increased renal membrane SGLT2 expression (by 38-56%) and reduced the expression of SGLT1 (by 33-37%) vs. vehicle-treated wild-type controls (WT). The diabetes-induced changes in SGLT2/SGLT1 protein expression are expected to enhance the BG-lowering potential of SGLT2 inhibition, and empagliflozin strongly lowered BG in Akita (means of 187-237 vs. 517-535 mg/dl in vehicle group; 100-140 mg/dl in WT). Empagliflozin modestly reduced GFR in WT (250 vs. 306 l/min) and completely prevented the diabetes-induced increase in glomerular filtration rate (GFR) (255 vs. 397 l/min). Empagliflozin attenuated increases in kidney weight and urinary albumin/creatinine ratio in Akita in proportion to hyperglycemia. Empagliflozin did not increase urinary glucose/creatinine ratios in Akita, indicating the reduction in filtered glucose balanced the inhibition of glucose reabsorption. Empagliflozin attenuated/prevented the increase in systolic blood pressure, glomerular size, and molecular markers of kidney growth, inflammation, and gluconeogenesis in Akita. We propose that SGLT2 inhibition can lower GFR independent of reducing BG (consistent with the tubular hypothesis of diabetic glomerular hyperfiltration), while attenuation of albuminuria, kidney growth, and inflammation in the early diabetic kidney may mostly be secondary to lower BG. 
 Question: Which protein does empagliflozin inhibit?

A: sglt2
****
Q: Context: In August 2009, Ocwen completed the distribution of its Ocwen Solutions (OS) line of business via the spin-off of a separate publicly traded company, Altisource (NASDAQ: ASPS). 
 Question: Which exchange is Ocwen listed with?

A:
nasdaq
****